# Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

Study · id `cardio:ct-nct07273838` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07273838](<https://clinicaltrials.gov/study/NCT07273838>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07273838

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

## Technical summary

Registry record NCT07273838. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-05 (actual); primary completion 2028-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT07273838, source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)
- Started: 2026-03-05 (actual) (ClinicalTrials.gov record NCT07273838, source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)
- Primary completion: 2028-08-31 (anticipated) (ClinicalTrials.gov record NCT07273838, source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)
- Completion: 2029-10-31 (anticipated) (ClinicalTrials.gov record NCT07273838, source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07273838, source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07273838-2026-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
- Condition: Heart Failure
- Condition: Acute Kidney Injury
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Placebo
- Lead sponsor: Yale University
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Yale University (`cardio:org-yale-university`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: 8cc2deed0ece0c801e1af42c2989c0cb4b22fe0bba7d507ae9bd10bd40218a58
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
